Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-12-04
2010-02-23
Yaen, Christopher H (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
07666998
ABSTRACT:
The present inventors extensively studied and found that an antibody binding to PepT has cytotoxic activity and inhibits cell growth. These results suggest that an antibody binding to PepT, particularly an antibody having a cytotoxic activity, can be used as a cell growth inhibitor, for example, in treating and preventing cancer.
REFERENCES:
patent: 5500346 (1996-03-01), Bright et al.
patent: 5849525 (1998-12-01), Hediger
patent: 6270978 (2001-08-01), Bright et al.
patent: 6713278 (2004-03-01), Bouvier et al.
patent: 6867017 (2005-03-01), Dean et al.
patent: 2005/0004227 (2005-01-01), Saitoh
patent: 2005/0222391 (2005-10-01), Kodama et al.
patent: 2005/0281825 (2005-12-01), Kodama et al.
patent: 2006/0084119 (2006-04-01), Saitoh et al.
patent: 2006/0210569 (2006-09-01), Kodama et al.
patent: 2008/0040820 (2008-02-01), Kodama et al.
patent: 9676557 (1997-06-01), None
patent: 1142473 (2001-10-01), None
patent: 1 731 032 (2006-12-01), None
patent: 6-261761 (1994-09-01), None
patent: 8-134100 (1996-05-01), None
patent: 11-172 (1999-01-01), None
patent: 2001-197846 (2001-07-01), None
patent: 2001-139496 (2005-05-01), None
patent: WO 97/19919 (1997-06-01), None
patent: WO 98/46777 (1998-10-01), None
patent: WO 00/28016 (2000-05-01), None
patent: WO 03/033024 (2003-04-01), None
patent: WO 03/047621 (2003-06-01), None
patent: WO 03/083116 (2003-10-01), None
patent: WO 03/104453 (2003-12-01), None
Sun D. et al., “Drug Inhibition of Gly-Sar Uptake and hPepT1 Localization using hPepT1-GFP Fusion Protein”, AAPS PharmSci., vol. 3(1), pp. 1-9 (2001).
Sai Y. et al., “Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of β-lactam antibiotics”, FEBS Lett, vol. 392(1), pp. 25-29 (1996).
Basu SK et al., “Development and Utility of Anti-PepT1 Anti-Peptide Polyclonal Antibodies”, Pharmaceutical Research, vol. 15(2), pp. 338-342 (1998).
Gonzalez DE et al., Cancer Res., vol. 58(3), pp. 519-525 (1998).
Knutter et al., “A Novel Inhibitor of the Mammalian Peptide Transporter PEPT1”, Biochemistry, vol. 40(14), pp. 4454-4488 (2001).
Mrsny RJ., “Olgiopeptide Transporters as Putative Therapeutic Targets for Cancer Cells”, Pharm Res. vol. 15(6), pp. 816-818 (1998).
Nakanishi T. et al., “Cancer Cell-Targeted Drug Delivery Utilizing Oligopeptide Transport Activity”, Int. J. Cancer, vol. 88(2), pp. 274-280 (2000).
Gonzalez DE et al., “An Olgiopeptide Transporter Is Expressed at High Levels in the Pancreatic Carcinona Cell Lines AsPc-1 and Capan-2I”, Cancer Res., vol. 58(3), pp. 519-525 (1998).
Sugano K. et al., Quantitive Structure-Intestinal Permeability Relationship of Benzamidine Analogue Thrombin Inhibitor, Bioorg Med. Chem. Lett, vol. 10(17), pp. 1939-1942 (2000).
Zhou X. et al., “Characterization of an oligopeptide transporter in renal lysosomes”, Biochim Biophys Acta, vol. 1466(1-2), pp. 372-378 (2000).
Lee VHL et al., “Biopharmaceutics of transmucosal peptide and protein drug administration: role of transport mechanisms with a focus on the involvement of PepT1”, J. Control Release, vol. 62(1-2), pp. 129-140 (1999).
Loisel TP et al., “Recovery of homogeneous and functional β2-adrenergic receptors from extracellular baculovirus particles”, Nat Biotechnol, vol. 15(12), pp. 1300-1304 (1997).
Mangor JT et al., “A GP64-Null Baculovirus Pseudotyped with Vesicular Stomatitis Virus G Protein”, Journal of Virology, vol. 75(6), pp. 2544-2556 (2001).
Szakács G et al., “Characterization of the ATPase Cycle of Human ABCA1: Implications for Its Function as a Regulator Rather Than an Active Transporter”, Biochem Biophys Res Commun, vol. 288(5), pp. 1258-1264 (2001).
Noe J et al., “Characterization of the Mouse Bile Salt Export Pump Overexpressed in the Baculovirus System”, Hepatology, vol. 33(5), pp. 1223-1231 (2001).
Sakaguchi T. et al., “The Ion Channel Activity of the Influenza Virus M2Protein Affects Transport through the Golgi Apparatus”, J Cell Biol., vol. 133(4), pp. 733-747 (1996).
Mikhailov MV et al., “Expression of functionally active ATP-sensitive K-channels in insect cells using baculovirus”, FEBS Lett, vol. 429(3), pp. 390-394 (1998).
Strehlow D. et al., “Retroviral membrane display of apoptotic effector molecules”, Proc Natl Acad Sci USA, vol. 97(8), pp. 4209-4214 (2000).
Basu et al., “Screening of Anti-PepT1 Antibodies Using Indirect ELISA,”Pharmaceutical Research, 13(9 Suppl.):S-37, Abstract No. APQ 1137 (1996).
Blissard et al., “Location, Sequence, Transcriptional Mapping, and Temporal Expression of the gp64 Envelope Glycoprotein Gene of theOrgyia pseudotsugataMulticapsid Nuclear Polyhedrosis Virus,”Virology, 170:537-555 (1989).
Friedman et al., “Characterization of the Intestinal Transport Parameters for Small Peptide Drugs,”J. Control. Release, 13:141-146 (1990).
Friedman et al., “Passive and Carrier-Mediated Intestinal Absorption Components of Two Angiotensin Converting Enzyme (ACE) Inhibitor Prodrugs in Rats: Enalapril and Fosinopril,”Pharm. Res., 6:1043-1047 (1989).
Ganapathy et al., “Proton-coupled solute transport in the animal cell plasma membrane,”Curr. Opin. Cell Biol., 3:695-701 (1991).
Higgins, “ABC Transporters: From Microorganisms to Man,”Annu. Rev. Cell Biol., 8:67-113 (1992).
Houdebine, “Transgenic animal bioreactors,”Transgenic Res., 9:305-320 (2000).
Kolb et al., “Insertion of a foreign gene into the β-casein locus by Cre-mediated site specific recombination,”Gene, 227:21-31 (1999).
Lariviere et al., “Transgenic Studies of Pain and Analgesia: Mutation or Background Genotype?”J. Pharmacol. Exp. Ther., 297:467-473 (2001).
Leiter, “Mice with targeted gene disruptions or gene insertions for diabetes research: problems, pitfalls, and potential solutions,”Diabetologia, 45:296-308 (2002).
Liang et al., “Human Intestinal H+/Peptide Cotransporter. Cloning, Functional Expression, and Chromosomal Localization,”J. Biol. Chem., 270:6456-6463 (1995).
Lindley et al., “Production of monoclonal antibodies using recombinant baculovirus displaying gp64-fusion proteins,”J. Immunol. Methods, 234:123-135 (2000).
Liu et al., “Molecular cloning of PEPT2, a new member of the H+/peptide cotransporter family, from human kidney,”Biochim. Biophys. Acta, 1235:461-466 (1995).
Mancini et al., “Induction of Anti-Hepatitis B Surface Antigen (HBsAg) Antibodies in HBsAg Producing Transgenic Mice: A Possible Way of Circumventing ‘Nonresponse’to HBsAg,”J. Med. Virol., 39:67-74 (1993).
Muranushi et al., “Transport Characteristics of Ceftibuten, a New Oral Cephem, in Rat Intestinal Brush-Border Membrane Vesicles: Relationship to Oligopeptide and Amino β-Lactam Transport,”Pharm. Res., 6:308-312 (1989).
Murray, “Genetic Modification of Animals in the Next Century,”Theriogenology, 51:149-159 (1999).
Nakashima et al., “Kinetics and Mechanism of In Vitro Uptake of Amino-β-Lactam Antibiotics by Rat Small Intestine and Relation to the Intact-Peptide Transport System,”Biochem. Pharmacol., 33:3345-3352 (1984).
Ogihara et al., “Immuno-Localization of H+/Peptide Cotransporter in Rat Digestive Tract,”Biochem. Biophys. Res. Commun., 220:848-852 (1996).
Okano et al., “H+0 Coupled Uphill Transport of Aminocephalosporins via the Dipeptide Transport System in Rabbit Intestinal Brush-border Membranes,”J. Biol. Chem., 261:14130-14134 (1986).
Sai et al., “Selective Delivery of Peptide Anticancer Drugs via Oligopeptide Transporter Expressed in Cancer Cells,”Proceedings of the Millennium World Congress of Pharmaceutical Science, p. 61, Abstract No. 2-2124 (Apr. 16-20, 2000).
Saito et al., “Cloning and Characterization of a Rat H+/Peptide
Hamakubo Takao
Kodama Tatsuhiko
Ohizumi Iwao
Saitoh Ryoichi
Chugai Seiyaku Kabushiki Kaisha
Fish & Richardson P.C.
Yaen Christopher H
LandOfFree
Cell growth inhibitor containing anti-PepT antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell growth inhibitor containing anti-PepT antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell growth inhibitor containing anti-PepT antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162954